Ibrahim Al-khyate։ New Evidence on Triple Antithrombotic Therapy After Anterior Myocardial Infarction
Ibrahim Al-khyate, Cardiology Resident at Ministry of Health and Population – Egypt, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Clinical and Applied Thrombosis/Hemostasis, adding:
”Excited to share our latest publication in Clinical and Applied Thrombosis/Hemostasis!
Our updated systematic review and meta-analysis has now been published in SAGE Journals.
7 studies | 2,273 patients
Research question
Does adding prophylactic triple antithrombotic therapy to dual antiplatelet therapy after anterior myocardial infarction reduce the risk of left ventricular thrombus without compromising patient safety?
Main findings
- No significant reduction in left ventricular thrombus
- No reduction in all-cause mortality
- No reduction in thromboembolic events
Increased risk of major bleeding
Take-home message:
Current evidence does not support the routine use of prophylactic triple antithrombotic therapy after anterior myocardial infarction.
Antithrombotic therapy should be individualized, balancing thrombotic and bleeding risks.
Sincerely grateful to my co-authors and mentors for their dedication, insightful discussions, and collaboration throughout this project.
Looking forward to future collaborations and continuing to contribute to meaningful cardiovascular research.”
Title: Triple Antithrombotic Therapy vs Dual Antiplatelet for Prevention of Left Ventricular Thrombus After Anterior Myocardial Infarction: An Updated Meta-Analysis
Authors: Mustafa Abomohsen, Ibrahim Elkhayat, Ahmed Elmorsy Mohamed, Abdul Hakim Almakadma, Zeyad Kholeif, Ahmed Farid Gadelmawla, Ameer Awashra, Muhammed A. Youssef, Osamah AlQassab, Mohamed Ghannam, Vikas Patel, Azad Mojahedi, Iyad Idries, Meena Farid, Moshe Gunsburg, Hal L. Chadow
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 19, 2026, 13:36Shobhna Ladva: Aspen Pharma EME Raises Awareness of Blood Clot Risks During Hormonal Transitions
-
Oct 19, 2026, 13:11Giulia Furnari: Connecting With Global Hematology Experts at IACH 2026
-
Oct 19, 2026, 12:46Andrew Choong: Recognizing Thrombosis Before It Becomes Life-Threatening
-
Oct 19, 2026, 11:37Beth Faiman: APSHO Fellows Celebrated for Advancing Hematology and Oncology Practice
-
Oct 19, 2026, 11:26Emanuele Pacini: Myelodysplastic Syndromes Research Featured at JSH Annual Meeting in Kyoto
-
Oct 19, 2026, 10:57Jesmond Dalli: How Erythroblasts Shape Neutrophil Development and Function
-
Oct 19, 2026, 10:41Hisham Fahmi: SCD – Should Gene Editing Begin Before Organ Damage?
-
Oct 19, 2026, 10:33Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval
-
Oct 19, 2026, 10:28Brig Tathagata Chatterjee: Acute Leukemias in AYAs at the Japanese Society of Hematology Conference